NSE · HESTERBIO
Hester Biosciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹73 Cr with net profit ₹15 Cr — a 20.24% net margin, versus 16.26% the period before.
Shareholding
As of 2026-06-30
- Promoter53.73%
- Public45.95%
- FII0.31%
- DII0%
11,961 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.17× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #15 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,87,521 Cr | 84.04 | 22.3 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,614 Cr | 42.43 | 4.69 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,986 Cr | 38.76 | 9.72 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,630 Cr | 102.81 | 22.99 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹21,248 Cr | 31.94 | 6.31 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹18,800 Cr | 28.62 | 4.82 | 15.87% | 20.04% |
| Shilpa Medicare Ltd. | ₹18,383 Cr | 64.64 | 7.09 | 9.39% | 17.67% |
| Marksans Pharma Limited | ₹14,973 Cr | 28.98 | 4.95 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,448 Cr | 54.09 | 6.24 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,738 Cr | 53.32 | 7.22 | 12.36% | 18.59% |
| Hester Biosciences Ltd.(this company) | ₹1,939 Cr | 36.55 | 5.38 | 15.45% | 41.81% |
AI analysis
AI-generated · google/gemini-2.5-flashHester Biosciences Ltd. (HESTERBIO) has a market capitalization of Rs 2147 Cr. The company's revenue for the last fiscal year was Rs 342.28 Cr, with a profit margin of 16.73%. Hester Biosciences Ltd. reported an EPS of 62.97 and a book value of 423.46. The promoter holding in the company is 53.73%.
Positives
- +The promoter holding is 53.73%, indicating a significant stake.
- +The company has a debt-to-equity ratio of 0.6, suggesting moderate leverage.
- +The dividend yield is 44%, which is substantial.
Negatives
- −Revenue growth was 2.2%, indicating slow sales expansion.
- −The P/E ratio is 129.74, which may be considered high relative to earnings.
- −No quarterly results have been disclosed since March 2026.
Financial performance
Hester Biosciences Ltd. reported revenue of Rs 342.28 Cr, representing a revenue growth of 2.2%. The net profit for the latest fiscal year was Rs 55.639 Cr. The company's EPS stands at 62.97. Quarterly revenue has fluctuated, with the latest reported quarter (Mar 2026) showing revenue of Rs 100.11 Cr and a net profit of Rs 15.98 Cr.
Profitability & Returns
The company's profit margin is 16.73%. Hester Biosciences Ltd. achieved a Return on Equity (ROE) of 15.45% and a Return on Capital Employed (ROCE) of 14.34%. The P/E ratio is 129.74. The dividend yield is reported at 44%.
Balance Sheet
Hester Biosciences Ltd. has a debt-to-equity ratio of 0.6. The book value per share is Rs 423.46. No information on current assets or liabilities is available in the provided data.
Ownership & Pledges
Public shareholding is 45.96%. There are no pledged shares by the promoters.
Data as of — price: 2026-09-10 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.